High-throughput screening (HTS), a major component of lead identification, often utilizes fluorescence-based assay technologies. For example, HTS kinase assays are formatted using a variety of fluorescence-based assay technologies including, but not limited to, dissociation enhanced lanthanide fluoroimmunoassay (DELFIA ® ), time-resolved fluorescence resonance energy transfer (TR-FRET), and fluorescence polarization (FP). These assays offer tremendous advantages such as a nonradioactive format, ease of automation, and excellent reproducibility. Fluorescence-based assays frequently used for lead identification can also be useful for structure activity relationship (SAR) studies during lead optimization. An important issue when assessing an assay to be used for SAR is the ability of the assay to discriminate high-affinity small molecule inhibitors (pM-nM) from low-affinity inhibitors (µM-mM). The purpose of this study was to utilize HTS-friendly assay formats for SAR by developing TR-FRET, FP, and DELFIA ® assays measuring Src kinase activity and to define the theoretical lower limit of small molecule inhibitor detection achievable with these assay formats. The authors show that 2 homogeneous assay formats, TR-FRET and FP, allowed for the development of Src kinase assays with a lower limit of detection of K i = 0.01 nM. This study indicates that assay technologies typically used for HTS can be used during lead optimization by providing quantitative measurements of compound activity critical to driving SAR studies. (Journal of Biomolecular Screening 2004:525-532) 
INTRODUCTION
P ROTEIN TYROSINE KINASES ARE CRITICAL to cell signaling and play a significant role in the regulation of various cellular functions including cell differentiation and cell growth. 1 Disruption of signaling mediated by members of the tyrosine kinase family has been linked to several disease states including cancer, diabetes, and immunological disorders. 2, 3 Several synthetic inhibitors are in clinical development as treatments for cancer. 4 Members of the Src family of tyrosine kinases have been well characterized as signaling molecules. Aberrant activity of members of the Src kinase family has been implicated in breast and colon cancer. 5 A challenge to drug development has been the identification of selective Src inhibitors that block Src kinase activity without perturbing the activity of Lck kinase (an Src kinase family member), which is involved in T-cell functioning. 6 A variety of fluorescence-based assay technologies are available for lead identification for use in high-throughput screening (HTS). 7 These technologies offer many advantages including radiation free, automation friendly formats, and reagent conservation by miniaturization of the assay. Time-resolved fluorescence resonance energy transfer (TR-FRET) and fluorescence polarization (FP) assay formats are 2 frequently used homogenous fluorescence-based HTS technologies. [8] [9] [10] Homogenous assays eliminate the need for wash steps that otherwise are required to separate unbound labeled molecules of interest from bound labeled molecules allowing detection of specific binding. Homogenous assay formats also have the advantage of detecting low-affinity interactions (µM) due to the elimination of disruptive steps in the assay protocol such as washing. Homogenous assay formats are typically used for lead identification in the context of HTS and a range of assay formats, often heterogenous, such as DELFIA ® and ELISA (enzyme-linked immunosorbent assay) are used for lead optimization. The choice of which assay format to use is based on several issues including the type of information needed, reagent, and equipment availability.
Assays for HTS are optimized for throughput and reproducibility to allow for the most accurate single-dose measurement of compound activity. For example, an HTS result defined as percent inhibition or percent activation is used to determine which compounds are active in a given screen. Further quantitative analysis of the activity of a given compound (IC 50 measurements) may be done by the original screening assay and confirmed with additional assay formats. Given the low potency of new leads (µM), HTS assays are typically not characterized for their ability to measure high-affinity small molecule inhibitors. During lead identification, potency measurement (IC 50 or K i measurements) of a compound is secondary to the initial goal of identifying potential leads within a large compound library. However, the assay technologies frequently used for HTS can measure low-and high-affinity small molecule inhibitors, making them useful tools for lead optimization.
The generation of structure activity relationship (SAR) around lead compounds requires panels of assays to provide information (IC 50 values, K i values) regarding potency and selectivity of small molecules of interest. When targeting a kinase molecule, a variety of different biochemical and cellular assays may be used to evaluate the potency and selectivity of interesting lead compounds. The primary assay, which is used to drive SAR, must be accurate, reproducible, and of sufficient throughput to manage the compound numbers generated during lead optimization (medicinal chemistry, focused combinatorial chemistry). Quantitative, automationcompatible assays are desirable in SAR studies to triage compounds during lead optimization. Given that each IC 50 or K i value is generated from a dose-response curve requiring multiple data points, the number of compounds generated by chemists, focused libraries, and modeling efforts can often exceed the capacity of manually run ELISA and DELFIA ® assays. Furthermore, it is desirable that an assay used for SAR be able to accurately measure compound potency down to the pM-nM range that is typical of a fully optimized lead compound. The upper and lower limit of the potency range that is measurable by an assay is useful information. For the purpose of this study, the term assay "lower limit" is used to describe the lowest K i value for which a given assay can generate an accurate value.
There are several important criteria when identifying a format for a primary biochemical kinase assay for lead optimization. Several of the criteria for the development of a lead optimization assay are identical to those for the development of an HTS assay. Assay reproducibility and performance are important and can be defined by several factors including signal to background (S/B), signal to noise (S/N), and Z′ factor. 11 Throughput and cost are also considerations in choosing an assay technology for a primary assay, though the requirements for throughput are distinct between an HTS screen and a lead optimization program. The biochemical parameters of the assay and reagent quality are of highest priority in developing a useful assay for lead optimization. The conditions under which the kinase activity is measured (enzyme/substrate concentration relative to K m ) will determine assay sensitivity. Given the promiscuity of kinases, different substrates are available when designing a kinase assay. The kinase activity measured can differ with different substrates. 12 Reagent limitations or new insights into the biochemistry of the target kinase may necessitate the need to develop additional assays during the course of lead optimization. However, this can lead to complications in the correlation of data between assays. Ideally, a single primary assay will be used for the duration of SAR studies. The assay should accurately differentiate between low-and high-affinity compounds of interest. During the course of lead optimization, compound potency may be initially in 10-50 µM range and subsequently be driven to potency in the pM-nM range.
IC 50 values are standard measurements used to assess the potency of inhibition of protein function by a small molecule inhibitor. For kinase targets, when assessing ATP-competitive inhibitors, a K i value can be derived from an IC 50 measurement if the K m ATP is established. An IC 50 value is by definition the concentration of inhibitor where 50% loss in protein activity is measured. The concentration of an inhibitor that occupies 50% of ATP binding sites is the minimal measurable IC 50 value. Consequently, the lowest IC 50 value measurable in the assay cannot be less than 50% of the concentration of the kinase present in the assay. For an ATP-competitive inhibitor, the true assay lower limit (i.e., the lowest K i value that can be measured) will also depend on the concentration of ATP present in the assay, because the relationship of IC 50 to K i is ATPconcentration dependent.
Given the high interest in Src kinase as a target molecule for drug development and as a desirable candidate molecule for understanding drug selectivity, we chose to use Src kinase as a model system in the evaluation of several HTS assay formats. 13, 14 The assay formats chosen for this study are based on timeresolved fluorescence and fluorescence polarization. We chose to focus our efforts on homogenous assay formats TR-FRET and FP in that they are in routine use in HTS for lead identification and are readily amenable to automation. [15] [16] [17] We also chose a heterogeneous time-resolved fluorescence assay format (DELFIA ® ), which is representative of plate-based assays used both in HTS and lead optimization.
MATERIALS AND METHODS

Materials
Src kinase was purchased from Upstate Biotechnology (Waltham, MA). One unit of Src kinase is defined as the amount of kinase that will phosphorylate 1 pmol of peptide (KVEKIGEGTYGVVYK) corresponding to amino acids 6-20 of p34cdc2, per minute at 30°C in the presence of 100 µM ATP. Biotinylated RRLEEEEEAYG (R11G) was synthesized by Tufts (Boston, MA), biotinylated PolyGT was obtained from CIS Biointernational (Bagnols-ser-Ceze, France), and biotinylated KVEKIGEGTYGVVYK (K15K) was obtained from ANA SPEC (San Jose, CA). All chemicals were of analytical or research grade. DMSO was purchased from Fisher Scientific (Pittsburgh, PA). ATP was purchased from Invitrogen (Carlsbad, CA). An LJL Analyst plate reader (Molecular Devices Corp, Sunnyvale, CA) was used for all measurements.
Time-resolved fluorescence (TRF): DELFIA ® assay
Clear 96-well Streptavidin (SA) plates (Perkin Elmer, Boston, MA) were coated overnight at 4°C with 100 ng/well of biotin-R11G prepared in 50 mM HEPES, pH 7.5, containing 0.1 mg/mL (w/v) bovine serum albumin (BSA). Plates were washed with PBS containing 0.05% (v/v) Tween20, blocked with Tris-Superblock (Pierce, Rockford, IL) for 1 h at room temperature and washed with PBS containing 0.05% (v/v) Tween20. For the Src kinase reaction, 10 µL of 5% (v/v) DMSO was added to each well, followed by the addition of 20 µL of 2.5 nM Src kinase to each well. The reaction was initiated by the addition of 20 µL of 25 µM ATP. Unless specified otherwise, the final concentrations in the reaction well were 1% (v/v) DMSO, 1 nM Src, and 10 µM ATP. The reaction and all dilutions were prepared in assay buffer (AB) containing 50 mM HEPES (pH 7.5), 60 mM NaCl, 1 mM MgCl 2 , 5 mM DTT, 5 mM MnCl 2 , and 0.1 mM Na 3 VO 4 . The kinase reaction was incubated at room temperature for 30 min and stopped with the addition of 180 µl of 65 mM EDTA. Plates were washed with PBS containing 0.05% (v/v) Tween20. 100 µL of 250 ng/mL Europium-N1 PT66 (anti-phosphotyrosine antibody) (Perkin Elmer, Boston, MA) in AB containing 0.75% (w/v) BSA (Perkin Elmer, Boston, MA) was added to each well and incubated at room temperature for 1 h. Plates were washed with PBS containing 0.05% (v/v) Tween20. 100 µL of Enhancement Solution (Perkin Elmer, Boston, MA) was added to each well and incubated for 2 h at room temperature. Plates were read on an LJL Analyst in time-resolved fluorescence mode for Europium signal (excitation 360 nm, emission 620 nm, and 100,000 µs integration time). Plates were washed with Elx405 (BIO TEK) plate washer 4 × with 200 µL per wash cycle of wash buffer (PBS containing 0.05%[v/v] Tween20). Control wells measuring total signal, contained 1% (v/v) DMSO only (no test compound). Control wells measuring background signal contained either 1% (v/v) DMSO/50 mM EDTA or AB without ATP.
TR-FRET assay
10 µL of 4%(v/v) DMSO/test compound was added to wells of a black 96-well plate (Perkin Elmer, Boston, MA). 10 µL of 400 nM PolyGT was added to each well. This was followed by the addition of 10 µL of 0.4 nM Src kinase to each well. The kinase reaction was initiated with the addition of 10 µL of 40 µM ATP. Unless specified otherwise, the final concentrations in the reaction well were 1% (v/v) DMSO, 0.1 nM Src, 100 nM PolyGT, and 10 µM ATP. All reagents were prepared in AB as described for DELFIA ® assay. The kinase reaction was incubated at room temperature for 30 min and stopped with the addition of 10 µL of 250 mM EDTA. 150 µL of a solution containing 240 ng/mL Europium Cryptate labeled anti-phosphotyrosine (PT66) antibody (CIS Biointernational, Bagnols-ser-Ceze, France) and 20 nM XL665labeled streptavidin (CIS Biointernational, Bagnols-ser-Ceze, France) in 50 mM HEPES (pH 7) containing 3% (w/v) KF and 0.1% (w/v) BSA was added to each well. Plates were incubated for 1 h at room temperature and read on an LJL Analyst where signal from both XL665 and Europium were acquired. The settings for LJL Analyst were 50 µs time delay and 400 µs read. The signal ratio (∆F) of APC and Eu (665 nm/615 nm) was used for data analysis. Control wells measuring total signal contained 1% (v/v) DMSO only (no test compound). Control wells measuring background signal contained either 1% (v/v) DMSO/50 mM EDTA or AB without ATP.
Fluorescence polarization (FP) assays
The FP assay was developed using Tyrosine Kinase Fluorescence Polarization Green Kit (PanVera, Madison, WI). First, 10 µL of 4% (v/v) DMSO/test compound was added to each well of a black 96-well plate (ThermoLab Systems, MA). 10 µL of 32 nM PolyGT was added to each well. This was followed by the addition of 10 µL of 0.4 nM Src kinase to each well. The kinase reaction was initiated with the addition of 10 µL of 40 µM ATP. Unless specified otherwise, the final concentrations in the reaction well were 1% (v/v) DMSO, 0.1 nM Src, 8 nM PolyGT, and 10 µM ATP. All reagents were prepared in AB as described for DELFIA ® assay. The kinase reaction was incubated at room temperature for 30 min and stopped with the addition of 10 µL of 250 mM EDTA. Antiphosphotyrosine antibody and PTK Green tracer were added to each well as per manufacturer instructions. Fluorescence polarization of each well was read on an LJL Analyst. The excitation filter wavelength was 485 nm. The emission filter wavelength was 530 nm. The integration time used was 100,000 µs. Control wells measuring background signal contained either 1% (v/v) DMSO/50 mM EDTA or AB without ATP.
Statistical parameters
The S/B ratio was calculated by S/B = mean X 2 /mean X 1 , where X 1 is the minimal signal obtained as measured from the content of the background control wells and X 2 is the maximal signal obtained as measured from the content of the total control wells. The S/N ratio was calculated as the mean of X 2 -mean of X 1 /standard deviation of X 1 . The Z′ value was calculated by Z′ = 1 -(3 · S 2 + 3 · S 1 )/ X 2 -X 1 , where S 1 and S 2 are the standard deviation of the minimal and maximal signal (X 1 and X 2 , respectively). S/B and S/N data reported during assay development are representative of 4 total signal control wells (S) and 4 background signal control wells (B) on High-Throughput Screening Kinase Assays for SAR a given 96-well plate. The Z′ values are determined from four 96well plates, each containing 88 total signal control wells and 12 background signal control wells.
RESULTS AND DISCUSSION
Assay development
Since the assay lower limit (i.e., the lowest K i value for which the assay can generate an accurate value) is a function of the concentration of enzyme, the initial assessment of each assay format was the detection of a specific signal with varying concentrations of Src kinase. Figure 1 shows typical titration curves obtained for Src kinase as measured by DELFIA ® (A), TR-FRET (B), and FP (C) assay formats. All 3 assay formats were able to measure specific Src-dependent phosphorylation of substrate. In the DELFIA ® assay, the signal increased from background counts (71,000 ± 3000 FU) with no Src kinase to high counts (3.7 × 10 6 ± 1.7 × 10 5 FU) with high concentrations of Src (10 nM). The enzyme titration curve reached saturation with~2.5 nM Src. In the TR-FRET assay, the signal increased from background counts (10 ± 2 ∆ F) with no Src to high signal (4,000 ± 200 ∆ F) with high concentrations of Src (0.5 nM). The enzyme titration curve reaches saturation with 0.15 nM Src. In the FP assay, the mP decreased where no Src was present (140 ± 20 mP) to low mP (20 ± 20 mP) with high concentration of Src (0.5 nM). Saturation is achieved with~0.10 nM Src. Relatively high concentrations of Src were necessary to achieve specific signal by DELFIA ® in comparison to TR-FRET and FP. This suggests TR-FRET and FP assay formats are more amenable to detection of low levels of phosphorylated substrate. However, Src kinase can phosphorylate multiple substrates 18 and the substrate used in each assay format should be considered.
The preference of Src kinase for different peptide substrates was evaluated (Fig. 2) . Three peptide substrates were evaluated: PolyGT, K15K, and R11G. From this set of peptide substrates, PolyGT was identified as the preferred substrate of Src kinase by both TR-FRET ( Fig. 1B) and FP (Fig. 1C) Additional standard kinetic parameters were evaluated by TR-FRET and FP for Src kinase phosphorylation of PolyGT (Fig. 4) . The K m value for ATP is comparable by both assay formats: 3.3 µM ± 1.5 by TR-FRET ( Fig. 4A ) and 2 µM ± 1 by FP (Fig. 4C) . This is consistent with K m for ATP for Csk kinase (8 µM), a member of Src kinase family. 19 The K m values for PolyGT were 40 nM ± 10 by TR-FRET ( Fig. 4B) and 7 nM ± 1.5 by FP (Fig. 4D) . The K m PolyGT obtained by TR-FRET and FP appears to be distinct and may be due to the necessity for using different substrate concentrations in order to remain within the dynamic range of the assay. This difference in K m value obtained may be attributed to the different signal strength measured by a given substrate concentration in each assay format. The FP assay format is amenable to using a lower substrate concentration during the K m measurement than the TR-FRET assay format. This suggests that the K m measured by the TR-FRET assay may be higher than the true K m . Nonetheless, PolyGT is identified as a relatively high-affinity substrate for Src.
High-Throughput Screening Kinase Assays for SAR
PolyGT has also been identified as a high-affinity substrate for EGFR, a receptor tyrosine kinase, with a K m value of 70 nM (personal communication, 2003, D. Jaga).
Optimized assay conditions for TR-FRET and FP assays
Optimized assay conditions are shown in Table 1 . An assay concentration of 10 µM ATP was chosen because this concentration is above the K m for ATP and sufficiently low to allow for detection of ATP site inhibitors during lead optimization. Choosing a reaction time point within the initial rate region ensures that neither ATP nor PolyGT are a limiting component of the kinase reaction. Where the reaction proceeds beyond the initial rate region, the reaction would observe pseudo 1st-order rate kinetics for PolyGT. In this case, PolyGT would be the limiting substrate as the concentration of PolyGT is either at K m (FP) or twice K m (TR-FRET). The Src concentration and PolyGT concentrations were chosen based on the lowest concentration of each reagent that would produce a reliable signal. A Z′ factor of 0.77 and 0.83 was obtained for TR-FRET and FP, respectively. This indicates that the assay performs well at these assay conditions.
SAR measurements by TR-FRET and FP
The activity of known Src kinase inhibitors was measured by the different Src assays (TR-FRET, FP) to determine if the SAR profiles generated by the different assay formats are comparable or distinct. It has been previously established that different HTS assay formats can yield different hits in HTS despite measuring activity against the same protein target. 20 A panel of 11 known Src kinase inhibitors 21 was tested in the TR-FRET and FP assays. The inhibitors were chosen due to their mechanism of action as ATP analogues and for their potency over~2 log units. K i value compari- (Fig. 5 ) is observed. The potency of compounds measured by TR-FRET assay is underestimated relative to measurements by FP assay. Rank ordering of compounds by their potency as measured by TR-FRET and FP assays is similar ( Table  2 ). Both assay formats identify the same compounds to be high affinity (K i < 100 nM), mid affinity (K i 100-500 nM), and low affinity (K i > 500 nM). Although the absolute ranking of compound potency (1 through 11) is distinct, the overall ranking is similar. Compounds K, I, and A are high affinity in both assays, and in comparison, compounds H, G, and E are of low affinity in both assays. The positive correlation observed in the K i values generated by the TR-FRET and FP assays and the rank ordering of potency of compounds suggests that the SAR profiles generated by either assay technology, with the assay conditions identified, would be comparable.
CONCLUSIONS
Robust assay conditions were identified using a low concentration of Src kinase (0.1 nM Src) for TR-FRET and FP assay formats. The DELFIA ® assay format was not amenable to the development of an assay with subnanomolar concentrations of Src kinase. The DELFIA ® assay format required the use of peptide substrate R11G rather than PolyGT, which is a preferred substrate for Src kinase by TR-FRET and FP assay formats. The assay conditions identified for TR-FRET and FP assay formats allow for quantitative measurements (IC 50 and K i values) of subnanomolar inhibitors of Src kinase activity.
It is important during lead optimization to know the lower limit of K i determination for drug candidates. This knowledge aids candidate selection and interpretation of SAR. For example, an apparent lack of improvement in potency of a lead series may be due to having reached the limit of detection of the assay being used to drive SAR. For small molecule SAR studies, it is desirable for an assay to discriminate the potency of inhibitors into the pM to nM range. In our Src kinase model system, we chose 0.1 nM Src kinase in each assay during assay development based on the lowest enzyme concentration that would reliably generate acceptable dynamic range and assay performance. When using either the TR-FRET or FP assay for SAR studies, regardless of the potency of the inhibitors of interest, there must be sufficient inhibitor present to occupy 50% of the enzyme and therefore observe 50% reduction in signal. This defines a practical lower limit for the IC 50 value as 0.05 nM. For very high-affinity inhibitors (true IC 50 values < 0.05 nM), these assays will be unable to differentiate their potencies. For ATP-competitive inhibitors, the Cheng-Prusoff factor can be 
FIG. 5.
Correlation study of Src kinase inhibitors (K i values) as measured by TR-FRET and FP assays. K i values were plotted in a scattergraph, and the line of equivalence is shown. IC 50 measurements (n = 11) were performed using 10-point curve in duplicate with a 3-fold dilution series of test compound. IC 50 values were calculated using a 4-parameter fit with Graphpad PRISM software. IC 50 values were converted to K i values using the Cheng-Prusoff equation (K m ATP = 3 µM). used to relate an experimentally derived IC 50 value to K i value based on the concentration of ATP used in the assay and the K m of ATP.
IC 50 = K i (1 + [ATP]/K m ATP ).
Having established the ATP K m by both assay formats to be~3µM, the Cheng-Prusoff factor relating IC 50 value to K i value can be calculated. Consequently, the theoretical lower limit of the assay for obtaining K i values of small-molecule ATP-competitive inhibitors is 0.01 nM. In practice, the detection limit of the assay will be higher due to imprecision from steps within the screening process; largely due to pipetting error and reagent purity.
We have used Src kinase as a model system to evaluate 3 HTS assay technologies for their utility in driving SAR; TR-FRET, FP, and DELFIA ® . TR-FRET and FP assay formats were preferred over DELFIA ® assay format due to the identification of assay conditions that enable detection of subnanomolar inhibitors of Src kinase. TR-FRET and FP assay measurements have practical utility for SAR studies. We established TR-FRET and FP assay conditions for use in small-molecule SAR for a kinase target. The assay conditions identified have a lower limit of detection of inhibitors in pM-nM range to differentiate between low-and high-affinity compounds. Although beyond the scope of this study, an additional advantage of TR-FRET and FP assay formats over DELFIA ® is the relative ease of conversion to higher throughput automated assays. As in HTS, this can be accomplished for the TR-FRET and FP assay formats by miniaturization and automation.
